ALEMBIC PHARMA | ALEMBIC | ALEMBIC PHARMA/ ALEMBIC |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 19.0 | 60.0 | 31.7% | View Chart |
P/BV | x | 7.3 | 5.2 | 142.0% | View Chart |
Dividend Yield | % | 0.5 | 0.2 | 263.3% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ALEMBIC PHARMA Mar-19 |
ALEMBIC Mar-18 |
ALEMBIC PHARMA/ ALEMBIC |
5-Yr Chart Click to enlarge
|
||
High | Rs | 664 | 72 | 922.2% | |
Low | Rs | 412 | 34 | 1,216.5% | |
Sales per share (Unadj.) | Rs | 208.7 | 4.7 | 4,440.2% | |
Earnings per share (Unadj.) | Rs | 31.0 | 6.1 | 507.9% | |
Cash flow per share (Unadj.) | Rs | 37.1 | 6.2 | 594.2% | |
Dividends per share (Unadj.) | Rs | 5.50 | 0.20 | 2,750.0% | |
Dividend yield (eoy) | % | 1.0 | 0.4 | 270.6% | |
Book value per share (Unadj.) | Rs | 144.2 | 40.7 | 354.7% | |
Shares outstanding (eoy) | m | 188.52 | 267.03 | 70.6% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.6 | 11.3 | 22.9% | |
Avg P/E ratio | x | 17.4 | 8.7 | 200.1% | |
P/CF ratio (eoy) | x | 14.5 | 8.5 | 171.1% | |
Price / Book Value ratio | x | 3.7 | 1.3 | 286.6% | |
Dividend payout | % | 17.7 | 3.3 | 541.5% | |
Avg Mkt Cap | Rs m | 101,461 | 14,139 | 717.6% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 7,467 | 207 | 3,600.2% | |
Avg. sales/employee | Rs Th | NM | NM | - | |
Avg. wages/employee | Rs Th | NM | NM | - | |
Avg. net profit/employee | Rs Th | NM | NM | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 39,347 | 1,255 | 3,134.7% | |
Other income | Rs m | 94 | 370 | 25.3% | |
Total revenues | Rs m | 39,441 | 1,625 | 2,426.5% | |
Gross profit | Rs m | 8,736 | 111 | 7,863.0% | |
Depreciation | Rs m | 1,152 | 38 | 3,048.4% | |
Interest | Rs m | 184 | 2 | 10,829.4% | |
Profit before tax | Rs m | 7,493 | 442 | 1,696.1% | |
Minority Interest | Rs m | 11 | 0 | - | |
Prior Period Items | Rs m | -93 | 1,212 | -7.7% | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 1,568 | 24 | 6,544.9% | |
Profit after tax | Rs m | 5,844 | 1,630 | 358.5% | |
Gross profit margin | % | 22.2 | 8.9 | 250.8% | |
Effective tax rate | % | 20.9 | 5.4 | 385.9% | |
Net profit margin | % | 14.9 | 129.8 | 11.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 19,577 | 1,867 | 1,048.5% | |
Current liabilities | Rs m | 14,896 | 591 | 2,519.7% | |
Net working cap to sales | % | 11.9 | 101.6 | 11.7% | |
Current ratio | x | 1.3 | 3.2 | 41.6% | |
Inventory Days | Days | 90 | 94 | 95.2% | |
Debtors Days | Days | 45 | 74 | 61.7% | |
Net fixed assets | Rs m | 27,097 | 1,791 | 1,513.0% | |
Share capital | Rs m | 377 | 534 | 70.6% | |
"Free" reserves | Rs m | 26,811 | 10,324 | 259.7% | |
Net worth | Rs m | 27,188 | 10,858 | 250.4% | |
Long term debt | Rs m | 4,993 | 41 | 12,118.9% | |
Total assets | Rs m | 47,778 | 11,591 | 412.2% | |
Interest coverage | x | 41.7 | 260.9 | 16.0% | |
Debt to equity ratio | x | 0.2 | 0 | 4,839.7% | |
Sales to assets ratio | x | 0.8 | 0.1 | 760.5% | |
Return on assets | % | 12.6 | 14.1 | 89.6% | |
Return on equity | % | 21.5 | 15.0 | 143.2% | |
Return on capital | % | 23.6 | 15.2 | 155.4% | |
Exports to sales | % | 0 | 1.5 | 0.0% | |
Imports to sales | % | 0 | 21.0 | 0.0% | |
Exports (fob) | Rs m | NA | 19 | 0.0% | |
Imports (cif) | Rs m | NA | 263 | 0.0% | |
Fx inflow | Rs m | 19,453 | 19 | 100,271.6% | |
Fx outflow | Rs m | 6,065 | 264 | 2,298.8% | |
Net fx | Rs m | 13,388 | -244 | -5,477.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 8,120 | 236 | 3,443.4% | |
From Investments | Rs m | -7,556 | -224 | 3,373.2% | |
From Financial Activity | Rs m | 590 | -27 | -2,219.5% | |
Net Cashflow | Rs m | 1,153 | -15 | -7,792.6% |
Indian Promoters | % | 74.1 | 64.0 | 115.8% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 2.9 | 0.2 | 1,450.0% | |
FIIs | % | 9.1 | 9.7 | 93.8% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 13.9 | 26.1 | 53.3% | |
Shareholders | 49,328 | 54,701 | 90.2% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC PHARMA With: WYETH PIRAMAL ENTERPRISES JUBILANT LIFE SCIENCES NEULAND LABS PFIZER
Compare ALEMBIC PHARMA With: MYLAN (US) ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Asian stock markets are trading on a mixed note today as disappointing news on US consumer spending dampened sentiment ahead of a closely-watched reading on the health of the Chinese economy.
For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.
For the quarter ended June 2019, ALEMBIC LTD has posted a net profit of Rs 20 m (down 70.9% YoY). Sales on the other hand came in at Rs 260 m (down 41.5% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.
More Views on NewsMy new guide will show you the huge potential in future proof businesses.
The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.
The charts are telling the bulls to be cautious.
Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
More